Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Multiple Sclerosis, Aging
Interventions: Exercise trial consisting of both cardiovascular and strength training; Other
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 60 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Lymphocytic Leukemia, Chronic
Interventions: obinutuzumab, rituximab, chlorambucil; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Southern Tick-Associated Rash Illness
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Disease, Acute Coronary Syndrome
Interventions: Multifaceted Intervention with pharmacist and IVR; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 91 Years
Enrollment: 14,573 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 15
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 12 more

Conditions: Congestive Heart Failure
Interventions: peripheral venous pressure measurements, standard clinical care; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions: Rosiglitazone, Recombinant human growth hormone + rosiglitazone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 4
States / cities: New York, New York

Conditions: Overweight or Obesity
Interventions: Olatorepatide, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 3
States / cities: Walnut Creek, California • Winter Park, Florida • San Antonio, Texas

Conditions: Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
Interventions: Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: Carlsbad, California • Miami, Florida • Tampa, Florida + 11 more

Conditions: Stress Disorders, Posttraumatic
Interventions: Hydrocortisone, D-Cycloserine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Interventions: Tagraxofusp, Fludarabine, Cytarabine, Dexamethasone, Vincristine, Azacitidine, Methotrexate, Cytarabine IT, Hydrocortisone; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 29
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 25 more

Conditions: Traumatic Brain Injury
Interventions: Brain Training Program 1, Brain Training Program 2; Behavioral
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 19 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes
Interventions: Vessel measurements; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Arrhythmia, Bradycardia
Interventions: Pacemaker; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: Not listed
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 51
States / cities: Anchorage, Alabama • Mobile, Alabama • Fullerton, California + 48 more

Conditions: Multiple Myeloma
Interventions: Velcade, Thalidomide, Dexamethasone, Adriamycin, Cisplatin, Cyclophosphamide, Etoposide; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Essential Tremor, Tremor
Interventions: Ethanol, Propranolol; Other · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Sexually Transmitted Diseases, Substance-Related Disorders
Interventions: Partner-Specific IMB-based HIV risk reduction intervention, Healthy Lifestyle; Behavioral
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 15 Years to 18 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cancer, Breast, Age-related Cognitive Decline, Cognitive Decline
Interventions: Not listed
Lead sponsor: Georgetown University; Other
Eligibility: 60 Years to 105 Years · Female only
Enrollment: 1,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Kidney Diseases
Interventions: Control, Protein, Protein + Exercise; Dietary Supplement · Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 30 Years to 80 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 2
States / cities: Chicago, Illinois • Urbana, Illinois

Conditions: Major Depressive Disorder
Interventions: (2R,6R)-Hydroxynorketamine hydrochloride, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Non-squamous, Non-Small Cell Lung Cancer
Interventions: Aglatimagene Besadenovec, Valacyclovir, Pembrolizumab, Docetaxel; Biological · Drug
Lead sponsor: Candel Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: NNC0662-0419, Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Lancaster, California • Lomita, California • Long Beach, California + 20 more

Conditions: Atrial Fibrillation, Coronary Artery Disease
Interventions: Regadenoson MRI, Gadobenate dimeglumine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib + an aromatase inhibitor, Palbociclib + Letrozole, Letrozole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Stroke
Interventions: Rehabilitation Therapy on Experimental Robotic Table and standard of care, Rehabilitation Therapy as part of Standard of Care (Control); Device · Genetic
Lead sponsor: Bright Cloud International Corp; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: North Brunswick, New Jersey • West Orange, New Jersey

Search by objective public record fields.

Skeletal Muscle Aging and Responsiveness in Aged People With MS

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

Investigation of Southern Tick-Associated Rash Illness (STARI)

Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence

Peripheral Venous Pressure (PVP) Trial

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Veteran Stress and Learning Study

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Brain Training to Enhance Frontal Lobe Reasoning

Retinal Vessel Measurements as Clinically Useful Predictors in Veterans

CAPTURE - Complete Automatic Pacing Threshold Utilization Recorded by EnPulse

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response

Partner-Specific HIV Risk Reduction Intervention for Drug-Using Adolescents

Older Breast Cancer Patients: Risk for Cognitive Decline

Intra Hemodialytic Oral Protein and Exercise (IHOPE)

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly (Clinical Trial)